35
Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Embed Size (px)

Citation preview

Page 1: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Mark Hoffman, Ph.D.Director – Translational Medicine

Aug 24, 2007

Shawnee Mission South

Page 2: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Bio-sketch

• Raytown South High School 1987

• BA - William Jewell College 1991– Oxford University 1990

• Ph.D. - University of Wisconsin 1996– 1994 internship at DNAStar

• Postdoctoral training – National Animal Disease Center (USDA) 1996-1997

Page 3: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

High school

• Science Honor Society– Knowledge Bowl

• Equal interest in science and social studies

Page 4: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

William Jewell College

• Oxbridge Honors Program– Molecular Biology Major– Semester in England studying bioethics

• Electives in political science– Cold War politics– International relations

Page 5: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Undergraduate summers

• UMKC– Learned how to do basic Microbiology tasks

• KU– Learned biochemical techniques– Protein purification– Small research problems

• Refolding of purified proteins

• JC Penney commission sales

Page 6: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

University of Wisconsin

• Department of Bacteriology

• Funded by biotechnology training program– NIH program provides tuition and stipend for

first 3 years– Requires internship in industry– Coursework outside major

Page 7: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Graduate school

• Years 1-2 – Classes– Identify research project

• Preliminary exams• Years 3 – x

– Research– Publications– Write thesis– Defend thesis

Page 8: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Staphylococcal enterotoxin A

• Causes food poisoning

• Activates immune system through unusual mechanism

• Are the two related?

Rhesus monkey umbilical cordblood stimulation assay

Page 9: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Molecular modeling

Sites associated with vomiting Sites associated with immune activity

Page 10: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Internship

• DNAStar

• Developed programs that perform DNA and protein sequence analysis– Immunology related algorithms to predict

immunogenic epitopes in proteins• Rational vaccine design

Page 11: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

NADC• National Animal Disease Center – USDA

• Ames, Iowa

• Research on diseases of importance to agriculture and human food safety

• Biosecurity level 2 and 3 barns

Page 12: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

EC 0157:H7• E. coli O157:H7

– Causes enterohemorrhagic colitis– 7% of cases progress to hemolytic uremic

syndrome

• Live oral vaccination

Clin. Diag. Immun. 1998 5:242-246

Page 13: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Cerner

• Software developer for Microbiology team– Respond to issues– Write programs

• Team leader– Responsibilities above + lead team

• Architect

• Solution Manager

Page 14: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Our VisionOur Vision• Begin where youwant to end:– Automate

enterprise workflow

– Connect the community

– Structure and analyze

– Create executable knowledge

• The objective: close the loop

Page 15: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Critical DecisionsCritical Decisions

Page 16: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

.

Cerner Millennium Solutions PortfolioCerner Millennium Solutions Portfolio

Innovation You Can Trust™

©2003 Cerner Corporation. All rights reserved. This document contains confidential information which may not be reproduced or transmitted without the expressed written consent of Cerner.Version 3.0

Community &Consumer Systems

PhysicianPortal

PowerLink

ConsumerRelationshipManagement

ConditionCenters

Call Center Bio-SurveillanceHealthSentry

SpecialtyCare Systems

CardiologyCVNet

OncologyPowerChartOncology

Women’sHealth Children’s Orthopedics Pulmonology Home Health

ProCall

ClinicalCenter Systems Clinical TrialsLaboratory

PathNetRadiology

RadNetImage

ManagementCerner ProVision

PharmacyPharmNet

Financial & OperationalSystems

PatientAccounting

ProFit

CostAccounting

Supply ChainProCure

HealthInfo. Mgmt.

ProFile

WorkforceManagement

OutcomesMeasurement

PowerInsight

ComparativeData

HealthFacts

Knowledge-DrivenCare Solutions

DecisionSupport Engine

Discern Expert

ReportingDiscern Explorer

PowerVision

Outcomes & BenchmarkingCerner APACHE

DrugDatabase

Cerner Multum

ReferentialKnowledge

Zynx

ExecutableKnowledge

DirectCare Systems

EMRPowerChart

CDR

AmbulatoryCare

PowerChart OfficeEmergency

FirstNetCritical Care

INet

Surgery &Anesthesia

SurgiNet

Acute CareCareNet

PowerOrders

Plans & Protocol Mgmt.

PowerPlan

Multi-ContributorDocumentation

PowerNote &PowerForms

ConnectivityTechnologies

InterfaceEngine

Open Engine

InterfaceLibraryOpenPort

Medical DeviceInterfaces

ApplicationDev. Kit

MobileSolutions

Health Economy DistributedDatabase EMPI

DistributedDatabase EMR

Access SystemsEnterprise

Master PersonIndex

RegistrationEnterprise

Registration Mgmt.

SchedulingEnterprise

Scheduling Mgmt.

Benefits Mgmt.Eligibility &

Med. Necessity

Inherent SolutionsClosed LoopMed. Process Meds Integration

HIPAACompliance

ClinicalDecisionSupport

ClinicallyDriven Revenue

Cycle

Clinically DrivenResourcePlanning

IndustrialStrength Early Maturity 2003 2004 2005 FutureKey

10 Solution Groups – 54 Solutions

Millennium Helix™

Page 17: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Public Health

Lab Result

Fill Out Forms by Hand

Fax to DOH

Fill out Log for HIM – HIPAA Compliance

Follow Up from DOH

Preparation of Internal IC

Reports by hand using multiple

systems

Automatic Reporting - HealthSentry

Daily Reports for Lab and IC

“Pushed” to HealthSentry

users

Page 18: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Public Health

HealthSentry Architecture

Page 19: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Daily Result Trending

Page 20: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

2006

Page 21: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

DATA COMPLETENESS Reportable cases (non-STD): March-Sept 2002

*Average over 6 key data fields

UNDER-REPORTING

0%

100%

200%

300%

400%

% I

nc

reas

e

0%

20%

40%

60%

80%

100%

Conventional HealthSentry

0.0

0.5

1.0

1.5

2.0

2.5

3.0

Conventional HealthSentry

TIMELINESS

% F

ield

s C

om

ple

te

*Average over all reportables

*Increased overall reporting by 96%

Da

ys

to r

ece

ive

rep

ort

HealthSentry – Proven Results

Page 22: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Present role• Director of Translational Medicine at Cerner

Corporation– Genomics– Biobanking– Clinical Trials– Registries– HIV Insights

• Lead group that is developing:– New software module(s)– Controlled vocabulary

Page 23: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Interoperability

• “You say tomato, I say tomato”

• Same meaning, different pronunciation

• Clinical example:– NA, Sodium, Sod = same meaning– EC, E. coli, Escherichia coli

Page 24: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Variant of like concept

• E. coli O157:H7

• E. coli O111:H11

• Bacillus

• Bacillus anthracis

Page 25: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South
Page 26: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

• Scope:• Molecular pathology• Clinical Genetics• Infectious disease• Cytogenetics• Cell surface markers

• Current state (Jun 2008):• 12,063 Concepts• 29,355 Relationships• 761 Genes• 1,239 Nucleotide variants • 6,923 Terms 

• 5,516 Facets  

• Available from: www.clinbioinformatics.org

• Included in the NCI Metathesaurus

The Clinical Bioinformatics Ontology (CBO)

Page 27: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Registered Users

Page 28: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Registered Users - Global

Page 29: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Unified Report

Default- uneditable

MultiMedia Foundation (MMF)

Document Results

Protocol

Page 30: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Policy Issues - Genetic Testing•SACGHS

•Ordering

•Reporting

•Interpretation

•Reimbursement

•American Health Information Community (AHIC)•Standardization

•Data exchange

•Family history

Page 31: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Clinical Utility of Genetic Testing

• Evaluating Genomics in Practice and Prevention• Working group – generates reports• Stakeholder group – guides priorities/communication of WG• Example: CYP2D6 genotyping in non-psychotic depression treated with

SSRI

• Encourage to extend literature review model to incorporate data and other analytical methods

Page 32: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Pharmacogenomics• Use of genetic information in the

selection of therapy.• Sometimes used to describe the

use of Genomics to identify drug targets.

• Mutations that affect ability to metabolize drugs– Adverse Reactions

• Halothane -> Malignant Hyperthermia - RYR1

– Dosage effects• Coumadin - CYP2C9

– No benefit• Codeine - CYP2D6

Page 33: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Opportunities

• Internships (High School or College)

• Clinical roles– Nurse– Medtech– Physician

• Technical roles– Software engineer– Systems engineer

Page 34: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Options during High School

Tier 2: Velocity Academic Interns (High School)

Summer following Sophomore year in high school

3.0 cumulative GPA or above Technical career interest or previous experience Cap of 10 associates for 2008

Tier 3: Student Associate 3.0 cumulative GPA or above in High School or College

Cap of 35 associates/summer

Page 35: Mark Hoffman, Ph.D. Director – Translational Medicine Aug 24, 2007 Shawnee Mission South

Decisions• Seemingly small decisions can have lasting

impact

• Try to open doors and avoid closing them

• A career in science doesn’t rule out:– Business– Policy– Management

• Never say “just” – about yourself or others

• Learn what you do well and what you don’t and then accept both